Epigenetic modifiers G9a and SIRT6 aid in mycobacterial pathogenesis.

(A-J) Mice were aerosolized with 200 CFU of H37Rv. (A) Schematic of in vivo mouse TB model for G9a inhibitor therapeutic treatment. (B) H37Rv CFU from the lungs and spleen of G9a inhibitor (40mg/kg) treated and untreated BALB/c mice was assessed after 56 days of total infection and therapeutic treatment. (C-D) Lungs of BALB/c mice from the indicated groups were analyzed for TB pathology by H & E staining; (C) representative image, (D) % of granulomatous area and (E) corresponding histological evaluation for granuloma score. (F) Schematic of in vivo Mtb infection model for WT (littermate control) and Sirt6−/+ mice. (G) CFU of H37Rv from the lung and spleen of WT (littermate control) and Sirt6−/+ mice were assessed following 56 days of H37Rv infection. (H, I) Lungs from the indicated groups of mice were analyzed by H and E staining; (H) representative images, (I) % of granulomatous area and (J) corresponding histological evaluation for granuloma score. N = 2 for Fig 6A, B; N = 1 for Fig 6C–6J. All data represents the mean ± SEM from 4–5 mice, *, P t-test for B, D, G and I). WT, Wild type; inh., inhibitor.